FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III

BACKGROUND: Immunotherapies may prolong the survival of patients with small-cell lung cancer (SCLC) to some extent. The role of forkhead box protein P3 (FOXP3) in tumor microenvironment (TME) remains controversial. We aimed to examine FOXP3-related expression characteristics and prognostic values an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Minlin, Wu, Chunyan, Zhang, Liping, Sun, Chenglong, Wang, Hao, Xu, Yi, Sun, Hui, Zhu, Jun, Zhao, Wencheng, Fang, Qiyu, Yu, Jia, Chen, Peixin, Wu, Shengyu, Zheng, Zixuan, He, Yayi, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137193/
https://www.ncbi.nlm.nih.gov/pubmed/34006632
http://dx.doi.org/10.1136/jitc-2021-002339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137193/
https://www.ncbi.nlm.nih.gov/pubmed/34006632
http://dx.doi.org/10.1136/jitc-2021-002339

Ejemplares similares